Key Points
- Director Richard Heyman sold 1,230 shares of Enliven Therapeutics at an average price of $26.18 for $32,201.40, reducing his direct stake by 5.15% to 22,647 shares; the transaction was disclosed in an SEC Form 4 filing.
- ELVN shares were trading around $26.19 (market cap ~$1.55B) and the stock carries a consensus analyst rating of “Moderate Buy” with a $41 consensus price target.
- Institutional ownership is very high at 95.08%, with several funds materially increasing positions recently—most notably Vestal Point (added 2.67M shares) and other large holders like Commodore, Polar Capital, Vanguard and State Street.
Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) Director Richard Heyman sold 1,230 shares of Enliven Therapeutics stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $26.18, for a total transaction of $32,201.40. Following the sale, the director directly owned 22,647 shares of the company's stock, valued at $592,898.46. This represents a 5.15% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.
Enliven Therapeutics Trading Up 0.1%
Shares of ELVN traded up $0.03 during trading hours on Friday, hitting $26.19. The company had a trading volume of 267,693 shares, compared to its average volume of 1,239,161. The company has a market capitalization of $1.55 billion, a PE ratio of -14.24 and a beta of 0.34. Enliven Therapeutics, Inc. has a one year low of $13.30 and a one year high of $30.22. The company's fifty day moving average price is $22.66 and its two-hundred day moving average price is $21.10.
Wall Street Analysts Forecast Growth
A number of research firms recently weighed in on ELVN. Wall Street Zen upgraded shares of Enliven Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, November 15th. Weiss Ratings reissued a "sell (d-)" rating on shares of Enliven Therapeutics in a research report on Wednesday, January 21st. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $41.00.
Read Our Latest Research Report on Enliven Therapeutics
Institutional Trading of Enliven Therapeutics
Institutional investors and hedge funds have recently bought and sold shares of the business. Commodore Capital LP lifted its holdings in Enliven Therapeutics by 0.4% in the 2nd quarter. Commodore Capital LP now owns 4,692,809 shares of the company's stock worth $94,138,000 after buying an additional 17,809 shares in the last quarter. Vestal Point Capital LP increased its position in shares of Enliven Therapeutics by 230.2% during the 4th quarter. Vestal Point Capital LP now owns 3,830,000 shares of the company's stock valued at $58,982,000 after purchasing an additional 2,670,000 shares during the period. Polar Capital Holdings Plc boosted its stake in shares of Enliven Therapeutics by 13.5% during the 4th quarter. Polar Capital Holdings Plc now owns 3,513,680 shares of the company's stock worth $54,111,000 after acquiring an additional 418,673 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Enliven Therapeutics by 5.9% during the third quarter. Vanguard Group Inc. now owns 2,553,014 shares of the company's stock valued at $52,260,000 after acquiring an additional 142,378 shares during the period. Finally, State Street Corp lifted its position in shares of Enliven Therapeutics by 9.1% in the fourth quarter. State Street Corp now owns 1,052,862 shares of the company's stock worth $16,214,000 after purchasing an additional 87,725 shares in the last quarter. Institutional investors and hedge funds own 95.08% of the company's stock.
About Enliven Therapeutics
(
Get Free Report)
Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.
The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
